Improving siRNA delivery strategies for cancer gene therapy
RNA interference-based therapeutics have demonstrated significant antiproliferative effects in preclinical animal models, and the first small interfering RNA (siRNA) cancer therapeutic entered clinical trials in 2008 with much promise. Effective delivery is now the most challenging hurdle remaining in the development of RNA interference as a broad therapeutic platform. Currently, systemic delivery of siRNA has been achieved through agents such as liposomes, cationic polymers, antibodies, aptamers, or other small molecular-weight ligands. My research will focus on improving targeted delivery strategies of siRNA to tumors to maximize efficacy while minimizing toxicity.